Comparison of simultaneously measured perfusion and BOLD signal increases during brain activation withT1-based tissue identification

Wen-Ming Luh; Eric C. Wong; Peter A. Bandettini; B. Douglas Ward; James S. Hyde

doi:10.1002/1522-2594(200007)44:1<137::aid-mrm20>3.0.co;2-r

Dissociation Between Individual Differences in Self-Reported Pain Intensity and Underlying Brain Activation

10.1101/2020.11.13.381970 ◽

2020 ◽

Author(s):

M.E. Hoeppli ◽

H. Nahman-Averbuch ◽

W.A. Hinkle ◽

E. Leon ◽

J. Peugh ◽

...

Keyword(s):

Individual Differences ◽

Pain Intensity ◽

Pain Sensitivity ◽

Pain Perception ◽

Objective Measure ◽

Brain Activation ◽

Individual Experience ◽

Bold Signal ◽

Pain Ratings ◽

Healthy Participants

AbstractPain is a uniquely individual experience. Previous studies have highlighted changes in brain activation and morphology associated with inter- and intra-individual pain perception. In this study we sought to characterize brain mechanisms associated with individual differences in pain in a large sample of healthy participants (N = 101). Pain ratings varied widely across individuals. Moreover, individuals reported changes in pain evoked by small differences in stimulus intensity in a manner congruent with their pain sensitivity, further supporting the utility of subjective reporting as a measure of the true individual experience. However, brain activation related to inter-individual differences in pain was not detected, despite clear sensitivity of the BOLD signal to small differences in noxious stimulus intensities within individuals. These findings raise questions about the utility of fMRI as an objective measure to infer reported pain intensity.

Download Full-text

Transient and sustained BOLD signal time courses affect the detection of emotion-related brain activation in fMRI

NeuroImage ◽

10.1016/j.neuroimage.2014.08.054 ◽

2014 ◽

Vol 103 ◽

pp. 522-532 ◽

Cited By ~ 5

Author(s):

Christian Paret ◽

Rosemarie Kluetsch ◽

Matthias Ruf ◽

Traute Demirakca ◽

Raffael Kalisch ◽

...

Keyword(s):

Brain Activation ◽

Bold Signal ◽

Time Courses ◽

Signal Time

Download Full-text

OP0117 LONGITUDINAL CHANGE IN THE CENTRAL NERVOUS SYSTEM PAIN RESPONSE AFTER TREATMENT WITH CERTOLIZUMAB OR PLACEBO. A POST-HOC ANALYSIS FROM THE PRECEPRA TRIAL

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2020-eular.5249 ◽

2020 ◽

Vol 79 (Suppl 1) ◽

pp. 77-78

Author(s):

J. Rech ◽

K. Tascilar ◽

H. Schenker ◽

M. Hagen ◽

M. Sergeeva ◽

...

Keyword(s):

Central Nervous System ◽

Nervous System ◽

Brain Activation ◽

Tnf Inhibitors ◽

Longitudinal Change ◽

Finger Tapping ◽

Bold Signal ◽

Research Support ◽

The Brain ◽

Tnf Inhibition

Background:Tumor necrosis factor inhibitors have revolutionized the treatment of rheumatoid arthritis (RA). However, only about 50% of the patients respond well to TNF inhibitors. Therefore, markers that predict response to TNF inhibitors are valuable. Previously we demonstrated that central nervous system (CNS) response to nociceptive stimuli, measured by fMRI of the brain as blood oxygen level dependent (BOLD) signals, decreases already after 24 hours of anti-TNF administration a higher pre-treatment BOLD signal volume seems to predict clinical response to treatment with certolizumabpegol (CZP)1,2. We therefore hypothesized that the baseline volume of BOLD signal in the CNS could predict anti-TNF treatment response.Objectives:To perform a randomized placebo controlled trial in active RA patients to test the effect of TNF inhibition on arthritis induced pain activity in the brain and to test whether patients with high-level RA-related brain activation react differently to TNF-inhibitors than patients with low-level brain activation.Methods:Adult RA patients fulfilling the 2010 ACR/EULAR classification criteria with a DAS28>3.2 receiving stable DMARD treatment for at least 3 months were eligible. Patients underwent the first fMRI at screening measuring BOLD signal upon MCP joint compression and were stratified into low (< 700 units) and high (>700 units) voxel counts. Then patients were randomized to CZP or placebo with a 2:1 ratio. The second and third fMRI were performed after 12 and 24 weeks, respectively. Control stimulation was done by measuring brain activation after non-painful finger tapping.Results:156 RA patients with moderate-to-high disease activity participated in the study. In the finger tapping control, fMRI showed no significant changes in BOLD signal in the CZP-L and CZP-H arms, but a slight but significant decrease (p=0.043) was observed. After joint compression, the CZP-L group showed significant increase in the BOLD signal volume (p=0.043) in fMRI-2 as compared to fMRI-1 with no further significant changes. In contrast, in the CZP-H group, the BOLD signal volume significantly decreased (p=0.037) in fMRI-2 and continued to decrease further, p=0.007. No significant changes were observed in the placebo arm over time.Conclusion:TNF inhibition improves arthritis-related brain activity in the subgroup of RA patients with high baseline BOLD activity in the fMRI.References:[1]Hess, A.et al.PNAS (2011).[2]Rech, J. et al. Arthritis & Rheumatism (2013).Fig 1.BOLD fMRI responses to painful stimulationAcknowledgments:The study was supported by an unrestricted grant of UCB Biopharma SPRL Brussels, BelgiumDisclosure of Interests:Jürgen Rech Consultant of: BMS, Celgene, Novartis, Roche, Chugai, Speakers bureau: AbbVie, Biogen, BMS, Celgene, MSD, Novartis, Roche, Chugai, Pfizer, Lilly, Koray Tascilar: None declared, Hannah Schenker: None declared, Melanie Hagen: None declared, Marina Sergeeva: None declared, Mageshwar Selvakumar: None declared, Laura Konerth: None declared, Jutta Prade: None declared, Sandra Strobelt: None declared, Verena Schönau: None declared, Larissa Valor: None declared, Axel Hueber Grant/research support from: Novartis, Lilly, Pfizer, EIT Health, EU-IMI, DFG, Universität Erlangen (EFI), Consultant of: Abbvie, BMS, Celgene, Gilead, GSK, Lilly, Novartis, Speakers bureau: GSK, Lilly, Novartis, David Simon Grant/research support from: Else Kröner-Memorial Scholarship, Novartis, Consultant of: Novartis, Lilly, Arnd Kleyer Consultant of: Lilly, Gilead, Novartis, Abbvie, Speakers bureau: Novartis, Lilly, Frank Behrens Grant/research support from: Abbvie, Pfizer, Roche, Chugai, Janssen, Consultant of: Abbvie, Pfizer, Roche, Chugai, UCB, BMS, Celgene, MSD, Novartis, Biotest, Janssen, Genzyme, Lilly; Boehringer; Sandoz, Speakers bureau: Abbvie, Pfizer, Roche, Chugai, UCB, BMS, Celgene, MSD, Novartis, Biotest, Janssen, Genzyme, Lilly; Boehringer; Sandoz, Christoph Baerwald Consultant of: CGB received speaker or consulting fees from AbbVie, Paid instructor for: CGB received speaker or consulting fees from AbbVie, Speakers bureau: CGB received speaker or consulting fees from AbbVie, Stephanie Finzel: None declared, Reinhard Voll: None declared, Eugen Feist Consultant of: Novartis, Roche, Sobi, Lilly, Pfizer, Abbvie, BMS, MSD, Sanofi, Speakers bureau: Novartis, Roche, Sobi, Lilly, Pfizer, Abbvie, BMS, MSD, Sanofi, José Antonio P. da Silva Grant/research support from: Pfizer, Abbvie, Consultant of: Pfizer, AbbVie, Roche, Lilly, Novartis, Arnd Doerfler: None declared, Nemanja Damjanov Grant/research support from: from AbbVie, Pfizer, and Roche, Consultant of: AbbVie, Gedeon Richter, Merck, Novartis, Pfizer, and Roche, Speakers bureau: AbbVie, Gedeon Richter, Merck, Novartis, Pfizer, and Roche, Andreas Hess: None declared, Georg Schett Speakers bureau: AbbVie, BMS, Celgene, Janssen, Eli Lilly, Novartis, Roche and UCB

Download Full-text

Task performance changes the amplitude and timing of the BOLD signal

Translational Neuroscience ◽

10.1515/tnsci-2017-0025 ◽

2017 ◽

Vol 8 (1) ◽

Author(s):

Atae Akhrif ◽

Maximilian J. Geiger ◽

Marcel Romanos ◽

Katharina Domschke ◽

Susanne Neufang

Keyword(s):

Task Performance ◽

Temporal Dynamics ◽

Brain Activation ◽

Bold Signal ◽

Bold Response ◽

Imaging Data ◽

Neural Firing ◽

Beta Band ◽

Beta Power ◽

Band Activity

AbstractTranslational studies comparing imaging data of animals and humans have gained increasing scientific interests. With this upcoming translational approach, however, identifying harmonized statistical analysis as well as shared data acquisition protocols and/or combined statistical approaches is necessary. Following this idea, we applied Bayesian Adaptive Regression Splines (BARS), which have until now mainly been used to model neural responses of electrophysiological recordings from rodent data, on human hemodynamic responses as measured via fMRI. Forty-seven healthy subjects were investigated while performing the Attention Network Task in the MRI scanner. Fluctuations in the amplitude and timing of the BOLD response were determined and validated externally with brain activation using GLM and also ecologically with the influence of task performance (i.e. good vs. bad performers). In terms of brain activation, bad performers presented reduced activation bilaterally in the parietal lobules, right prefrontal cortex (PFC) and striatum. This was accompanied by an enhanced left PFC recruitment. With regard to the amplitude of the BOLD-signal, bad performers showed enhanced values in the left PFC. In addition, in the regions of reduced activation such as the parietal and striatal regions, the temporal dynamics were higher in bad performers. Based on the relation between BOLD response and neural firing with the amplitude of the BOLD signal reflecting gamma power and timing dynamics beta power, we argue that in bad performers, an enhanced left PFC recruitment hints towards an enhanced functioning of gamma-band activity in a compensatory manner. This was accompanied by reduced parieto-striatal activity, associated with increased and potentially conflicting beta-band activity.

Download Full-text

The absence of task-related increases in BOLD signal does not equate to absence of task-related brain activation

Journal of Neuroscience Methods ◽

10.1016/j.jneumeth.2014.11.002 ◽

2015 ◽

Vol 240 ◽

pp. 125-127 ◽

Cited By ~ 6

Author(s):

Jiansong Xu ◽

Vince D. Calhoun ◽

Marc N. Potenza

Keyword(s):

Brain Activation ◽

Bold Signal

Download Full-text

Regional Frontal Lobe Response Magnitudes During Affective Shifting Covary With Resting Heart Rate Variability in Healthy Volunteers

Journal of Psychophysiology ◽

10.1027/0269-8803/a000166 ◽

2016 ◽

Vol 30 (4) ◽

pp. 165-174 ◽

Cited By ~ 3

Author(s):

Ryan Smith ◽

John J.B. Allen ◽

Julian F. Thayer ◽

Richard D. Lane

Keyword(s):

Heart Rate ◽

Heart Rate Variability ◽

Healthy Subjects ◽

Emotional Reactivity ◽

Bold Signal ◽

Resting Heart Rate ◽

Functional Magnetic Resonance ◽

Absolute Value ◽

Cardiac Vagal Control ◽

Resting Heart Rate Variability

Abstract. We hypothesized that in healthy subjects differences in resting heart rate variability (rHRV) would be associated with differences in emotional reactivity within the medial visceromotor network (MVN). We also probed whether this MVN-rHRV relationship was diminished in depression. Eleven healthy adults and nine depressed subjects performed the emotional counting stroop task in alternating blocks of emotion and neutral words during functional magnetic resonance imaging (fMRI). The correlation between rHRV outside the scanner and BOLD signal reactivity (absolute value of change between adjacent blocks in the BOLD signal) was examined in specific MVN regions. Significant negative correlations were observed between rHRV and average BOLD shift magnitude (BSM) in several MVN regions in healthy subjects but not depressed subjects. This preliminary report provides novel evidence relating emotional reactivity in MVN regions to rHRV. It also provides preliminary suggestive evidence that depression may involve reduced interaction between the MVN and cardiac vagal control.

Download Full-text